1 Min Read
(Reuters) - Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, adding to its portfolio of obesity drugs.
Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur
China receives US equipment to make advanced chips despite new rules - report
China receives US equipment to make advanced chips despite new rules-report
U.S. Treasury yields have peaked, say strategists for fourth straight month: Reuters poll
Google's expert in US antitrust trial defends billions paid to device makers
Post-strike Hollywood rushes to get film, TV sets humming
